These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9139416)

  • 1. [Possibilities and limitations of drugs to protect the liver].
    Schmid A; Schmid H
    Tierarztl Prax; 1996 Dec; 24(6):537-41. PubMed ID: 9139416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current problems in the treatment of hepatic cirrhosis].
    Oancea R
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1981; 33(4):303-10. PubMed ID: 6173910
    [No Abstract]   [Full Text] [Related]  

  • 3. [Are there any hepatoprotective drugs?].
    Policlinico Prat; 1971 Feb; 78(4):137-42. PubMed ID: 4102121
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipotropic agents and sulfur-containing amino acids.
    WHITE BV
    Conn State Med J; 1949 Apr; 13(4):349-52. PubMed ID: 18116255
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical importance of diets enriched with lipotropic factors in chronic hepatic lesions].
    Beiul EA; Iatsyshina TA; Volgarev MN; Korobkina GS; Odintsova IL; Kalinina NN; Trofimova OM
    Vopr Pitan; 1967; 26(4):40-5. PubMed ID: 4180800
    [No Abstract]   [Full Text] [Related]  

  • 6. [Modern indications for liver-protective therapy].
    Boll Soc Med Chir Cremona; 1954; 8(3-5):65-8. PubMed ID: 13230287
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of liver damage in sheep].
    Fürll M
    Berl Munch Tierarztl Wochenschr; 1996 Oct; 109(10):375-80. PubMed ID: 8999768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enzyme regulating therapy of hepatoses using lipocaic].
    Medgyesi G
    Med Klin; 1967 Feb; 62(6):213-6. PubMed ID: 4170729
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical experience with infusion therapy in chronic liver damage].
    EMMRICH R; PETZOLD H
    Z Klin Med; 1956; 154(3):237-51. PubMed ID: 13401979
    [No Abstract]   [Full Text] [Related]  

  • 10. [Protection induced by some pharmacological molecules with prevalent hepatoprotective activity against toxic effects provoked by hyperbaric oxygenation].
    Cerrati A
    Minerva Med; 1976 Aug; 67(38):2449-55. PubMed ID: 951065
    [No Abstract]   [Full Text] [Related]  

  • 11. [Results of lipocaine therapy of certain diseases of the liver].
    BONDAR' ZA; NAZARETIAN EL; PRISS IS
    Probl Endokrinol Gormonoter; 1956; 2(1):51-63. PubMed ID: 13322878
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pyridoxal phosphate-dependent enzymes of sulfur amino acid metabolism].
    Gabibov AG; Shuster AM; Khomutov AR; Tolosa EA; Goriachenkova EV
    Biokhimiia; 1989 May; 54(5):726-9. PubMed ID: 2758077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological and biochemical analysis of the action of Ornitaine on the diseased liver].
    Billiottet J
    Clinique (Paris); 1966 Jan; 60(615):67-70. PubMed ID: 4159874
    [No Abstract]   [Full Text] [Related]  

  • 14. [The use of different liver-protective substances in the course of antitubercular chemotherapy and their effectiveness in preventing and countering the appearance of metabolic and functional liver changes Clinico-statistical studies].
    Natale F; Perna G
    Arch Sci Med (Torino); 1979; 136(4):591-6. PubMed ID: 550759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial on a new combination of hepatoprotecting agents.
    Barlattani M
    Arzneimittelforschung; 1970 Apr; 20(4):560-5. PubMed ID: 4192590
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of active liver cirrhosis in patients maintained with amino acids intravenously as the source of protein and lipotropic substances.
    ECKHARDT RD; FALOON WW; DAVIDSON CS
    J Clin Invest; 1948 Jul; 27(4):531. PubMed ID: 18939297
    [No Abstract]   [Full Text] [Related]  

  • 17. [On the so-called hepatoprotective drugs. II. The so-called hepatoprotective drugs in the treatment of liver diseases].
    Mauro V
    Clin Ter; 1967 May; 41(3):265-86. PubMed ID: 4177978
    [No Abstract]   [Full Text] [Related]  

  • 18. [The influence of a new hepato-protective agent and detoxicant on pre-renal, renal and post-renal hyperazotemia].
    Olivieri V
    Minerva Med; 1966 Jan; 57(8):279-88. PubMed ID: 4159839
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lipotropic factors].
    DI LORENZO S
    Riforma Med; 1952 Jul; 66(29):805-6. PubMed ID: 13004694
    [No Abstract]   [Full Text] [Related]  

  • 20. [Behavior of certain liver function tests in hepatic disease treated with lipotropic substances].
    BANCHE M; CUGNASCO C
    Minerva Med; 1950 Jun; 41(30):1044-53. PubMed ID: 14775538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.